PhD, DABT, Vice President, Clinical Pharmacology & Non-Clinical Development
Aram Oganesian joined Astex Pharmaceuticals, Inc. in 2010 as a Director, Clinical Pharmacology. He has over 20 years of experience in pharmaceutical drug discovery & development, particularly in Toxicology, DMPK and Clinical Pharmacology. Before joining Astex, Dr. Oganesian held positions from Research Scientist to Section Head in Drug Safety & Metabolism Dept. at Wyeth Research (Pfizer since 2009) between 1997 and 2010, contributing to projects in Neuroscience (advanced multiple projects targeting Alzheimer’s disease into clinical development; approval of desvenlafaxine), Oncology (neratinib, bosutinib, sirolimus, temsirolimus), and other therapeutic areas (bazedoxifene). Dr. Oganesian earned an MS degree in Biology/Physiology from Moscow State University in 1992, and a PhD in Toxicology from Oregon State University in 1997, and also completed a program at Dartmouth College (Hanover HN) in Environmental Science and American Culture (1991). Dr. Oganesian was promoted in May 2019 to Vice President, Clinical Pharmacology & Non-Clinical Development. Dr. Oganesian is board certified as a Diplomate of the American Board of Toxicology.